Contribution: Industrial Research Assistance Program – Contributions to Firms
Incisive Genetics Inc.
$132,000.00
Route of Administration and Preclinical Efficacy of Gene Therapy
FY 2020-21 · 2020-06-01
Summary
This project will involve determining optimal route of administration of Transfection Competent Vesicle (TCV) delivery of gene editing machinery in vivo efficacy studies to generate critical proof of concept data, advance internal drug development and initiate possible pharma partnering opportunities.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Vancouver|Vancouver, British Columbia, Canada
Recipient Type
For-profit organization
Business Number
758555288
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2020-06-01 | 2020-21 | $142,000.00 |
| 1 | 2020-06-01 | 2020-21 | $132,000.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The total amended value is -10,000 dollars.
Additional Information (French)
Cet accord a été modifié 1 fois La valeur totale des modifications est de - 10 000 dollars.
Agreement End Date
2021-03-22
Agreement Number
952759
Agreement Start Date
2020-06-01
Agreement Title
Route of Administration and Preclinical Efficacy of Gene Therapy
Agreement Title (French)
Voie d'administration et efficacité préclinique de la thérapie génique
Agreement Type
Contribution
Agreement Value
$132,000.00
Amendment Date
2021-03-17
Amendment Number
1
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
This project will involve determining optimal route of administration of Transfection Competent Vesicle (TCV) delivery of gene editing machinery in vivo efficacy studies to generate critical proof of concept data, advance internal drug development and initiate possible pharma partnering opportunities.
Description (French)
Ce projet consistera à déterminer la voie optimale d'administration de la VCT (vésicule compétente de transfection) et à mener des études d'efficacité in vivo par machine d'édition génétique, et ce, afin de générer des données critiques de preuve de concept, de faire progresser le développement interne de médicaments et d'initier d'éventuelles possibilités de partenariats avec des entreprises pharmaceutiques.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Vancouver Quadra
Federal Riding (French)
Vancouver Quadra
Federal Riding Number
59039
NAICS Code
541710
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
758555288
Recipient City
Vancouver|Vancouver
Recipient Country
CA
Recipient Legal Name
Incisive Genetics Inc.
Recipient Postal Code
V6S 1Z3
Recipient Province or Territory
BC
Recipient Type
F
Reference Number
172-2020-2021-Q2-952759
